Ajanta Pharma: Business Overview & Financial Analysis
Ajanta Pharma Limited is a specialty pharmaceutical formulation enterprise headquartered in Mumbai, Maharashtra. Promoted by the Agrawal family, the company manufactures and markets branded generic formulations and generic medicines across more than 30 emerging and developed countries. Operating an integrated network of seven formulation manufacturing facilities in India, Ajanta Pharma holds therapeutic leadership in cardiology, ophthalmology, dermatology, and pain management across India, Asia, Africa, and the United States.
Geographic Revenue Breakdown of Ajanta Pharma (FY2026)
Ajanta Pharma distributes its specialty formulation products across domestic branded channels, emerging markets, and US generic markets.
- India Branded Generics – Rs 1,654 crore (30%)
- USA Generics – Rs 1,557 crore (29%)
- Emerging Markets Branded Generics (Asia & Africa) – Rs 1,749 crore (32%)
- Africa Institutional Business – Rs 493 crore (9%)
- Total Revenue from Operations – Rs 5,453 crore (100%)
Emerging market branded generics and domestic formulations form the primary core of the enterprise, offering high operating margins. The US business functions as an additional growth driver, powered by first-to-market ANDA generic approvals.
India Branded Generics & Therapeutic Mix of Ajanta Pharma (FY2026)
Ajanta Pharma ranks 24th in the Indian Pharmaceutical Market (IPM) according to IQVIA MAT March 2026 data, jumping two spots from the previous year.
- Cardiology / Cardiovascular Share – ~39% of India Sales
- Ophthalmology Share – ~28% of India Sales
- Dermatology Share – ~19% of India Sales
- Pain Management & Trade Generics – ~14% of India Sales
- Trade Generics Revenue – Rs 188 crore
- IPM Outperformance – 13% growth vs 10% IPM market growth
The company operates a domestic salesforce of over 4,000 medical representatives covering doctors and medical specialists. Outperformance against the IPM was driven by volume growth and 26 new product launches during the financial year.
International Business & US Generic Portfolio of Ajanta Pharma (FY2026)
Ajanta Pharma operates direct ground operations across 30+ emerging markets alongside an abbreviated new drug application (ANDA) pipeline in the United States.
- US Market Revenue – Rs 1,557 crore (+49% YoY)
- Asia Branded Generics Revenue – Rs 1,175 crore (-1% YoY)
- Africa Branded Generics Revenue – Rs 574 crore (+11% YoY)
- Cumulative US ANDA Approvals – 50+ approved products
- US Commercialized Products – 43 active generic products
The US business delivered 49% top-line growth in FY2026, driven by eight new generic product launches over a 15-month timeline. Branded generic operations across Asia and Africa feature ground teams servicing prescription demand.
Manufacturing Facilities & R&D Scale of Ajanta Pharma (FY2026)
Ajanta Pharma maintains seven manufacturing units across India, with dedicated USFDA-compliant sites.
- Formulation Manufacturing Plants – 7 operational plants (Paithan, Waluj, Chikalthana, Shendra, Dahej, Guwahati, Pithampur)
- USFDA-Approved Formulation Sites – Dahej (Gujarat) and Guwahati (Assam)
- Annual R&D Expenditure – ~6% of total operational turnover
- Dedicated R&D Personnel Count – 850+ scientists and researchers
Manufacturing operations focus entirely on finished dosage formulations, including tablets, capsules, eye drops, ointments, creams, and gels. R&D centers in Mumbai handle complex chemistry and sterile ophthalmic filings.
Key Performance Ratios & Capital Return Ratios of Ajanta Pharma (FY2026)
Ajanta Pharma tracks operational profitability and capital efficiency across financial reporting cycles.
- Gross Margin – 78.0%
- Operating EBITDA Margin – 26.0% (Excluding mark-to-market forex loss: 27.7%)
- Return on Capital Employed (ROCE) – 33.0%
- Return on Net Worth / Equity (ROE) – 25.0%
- Debt to Equity Ratio – Net Cash Positive (0.00x)
Gross margins reached 78% in FY2026 due to input cost normalization and high-margin branded formulation sales. Operating ROCE stood at 33%, demonstrating high capital productivity across formulation lines.
Latest Quarterly Financial Performance of Ajanta Pharma (Q4 FY2026)
Ajanta Pharma reported strong top-line growth and net profit expansion during the fourth quarter of FY2026.
- Consolidated Revenue from Operations – Rs 1,422 crore (+21.0% YoY)
- India Branded Sales (Q4 FY2026) – Rs 404 crore (+9.0% YoY)
- US Generic Sales (Q4 FY2026) – Rs 505 crore (+56.0% YoY)
- Operating EBITDA – Rs 333 crore (+12.0% YoY; Rs 375 crore ex-forex loss)
- Operating EBITDA Margin – 23.0% (26.0% ex-forex loss)
- Consolidated Net Profit After Tax (PAT) – Rs 267 crore (+18.0% YoY)
Fourth-quarter operating revenue rose 21% year-on-year to Rs 1,422 crore, driven by 56% growth in US generic sales. Adjusted EBITDA reached Rs 375 crore excluding a Rs 42 crore mark-to-market forex translation loss.
Consolidated Annual Financial Performance of Ajanta Pharma (FY2026)
Ajanta Pharma crossed significant financial milestones during the full financial year FY2026.
- Consolidated Revenue from Operations – Rs 5,453 crore (+17.0% YoY)
- Full Year Gross Profit – Rs 4,251 crore (78% Gross Margin)
- Full Year Operating EBITDA – Rs 1,395 crore (+11.0% YoY)
- Full Year Consolidated Net Profit After Tax (PAT) – Rs 1,056 crore (+15.0% YoY)
- Board-approved capital payout – Interim dividends totaling Rs 350+ crore
Full-year operating revenue crossed the Rs 5,000 crore milestone to reach Rs 5,453 crore, while Net Profit After Tax passed Rs 1,000 crore for the first time. Strong operational execution supported full-year EBITDA margins of 26%.
Management Commentary & Strategic Outlook of Ajanta Pharma (Q4 FY2026)
Management commentary highlights operational targets focused on fieldforce integration, US product launches, and margin protection.
- Management guides for FY2027 consolidated revenue growth in the 12%–14% range, supported by branded generic outperformance.
- Operating EBITDA margins are guided at 27.0% (+/- 1%) for FY2027, backed by operating leverage and product mix enrichment.
- Gross margins are projected to stabilize around 77.0% (+/- 1%) in upcoming quarters.
- Domestic medical representative teams will be scaled up to enhance doctor coverage across Tier-2 and Tier-3 cities.
- US generic launches are targeted at 6 to 8 new ANDA introductions during FY2027.
- Capital expenditure for FY2027 is budgeted at Rs 150–200 crore, funded entirely through internal cash accruals.
Management expects domestic branded formulations to maintain an outperformance corridor above IPM growth. Strategic priorities focus on integrating new sales teams, advancing the US ANDA pipeline, and sustaining net-cash balance sheet reserves.
Want to filter out stocks using your own financial benchmarks? You can use the Stock Screener on Finology Ticker to identify and compare companies based on specific growth and efficiency metrics.
Sources & References
- Ajanta Pharma Limited Q4 & Full Year FY2026 Earnings Conference Call Transcript (May 05, 2026)
- Ajanta Pharma Limited Q4 & Full Year FY2026 Consolidated Financial Results & Press Release (May 05, 2026)
- Ajanta Pharma Limited Q2 FY2026 Earnings Conference Call Transcript (November 03, 2025)
- BSE India & NSE Corporate Disclosures for Ajanta Pharma Limited
- Ticker Finology Ajanta Pharma Page
Disclaimer
The information presented above on Ajanta Pharma Limited has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Ajanta Pharma Limited page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.